Thomas Emrich

ORCID: 0000-0003-1179-4697
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Immunotherapy and Biomarkers
  • Protein purification and stability
  • Telomeres, Telomerase, and Senescence
  • Cancer, Hypoxia, and Metabolism
  • Glycosylation and Glycoproteins Research
  • Peptidase Inhibition and Analysis
  • Biosimilars and Bioanalytical Methods
  • Receptor Mechanisms and Signaling
  • Immune Cell Function and Interaction
  • Bacterial Identification and Susceptibility Testing
  • T-cell and B-cell Immunology
  • Nanoplatforms for cancer theranostics
  • Immune cells in cancer
  • Advanced biosensing and bioanalysis techniques
  • Molecular Biology Techniques and Applications
  • Parkinson's Disease Mechanisms and Treatments
  • RNA Interference and Gene Delivery
  • Radiopharmaceutical Chemistry and Applications
  • Platelet Disorders and Treatments
  • Microplastics and Plastic Pollution
  • Hemophilia Treatment and Research
  • Dysphagia Assessment and Management
  • HIV Research and Treatment
  • Bladder and Urothelial Cancer Treatments

Roche Pharma AG (Germany)
2004-2023

Roche (Switzerland)
2008-2021

Technical University of Munich
2021

Bioanalytica (Switzerland)
2015

Roche (Bosnia-Herzegovina)
2014

Biognosys (Switzerland)
2014

Sanquin
2004

München Klinik
1997

Max Delbrück Center
1993-1997

Ludwig-Maximilians-Universität München
1992-1994

Here, we investigated the influence of variable fragment (Fv) IgG antibodies on binding to neonatal Fc receptor (FcRn) as well FcRn-dependent pharmacokinetics (PK). FcRn plays a key role in homeostasis, and specific manipulation crystallizable (Fc) is known affect PK. Although antigen-binding (Fab) interactions has been reported, underlying mechanism hitherto only poorly understood. Therefore, analyzed two IgG1 antibodies, briakinumab ustekinumab, that have similar parts but different...

10.1073/pnas.1408766112 article EN Proceedings of the National Academy of Sciences 2015-04-27

The rapid diagnosis of an infectious cause in the course fever unknown origin plays a pivotal role correct management neutropenic patients. In this study, blood samples from febrile oncohaematological patients were tested using novel commercial real-time PCR assay (LightCycler Septi Fast ; Roche Molecular Systems) and culture (BacT/Alert 3D; bioMérieux). Twenty-one (20.4 %) 34 (33 103 under study positive by PCR, respectively. analysis concordance evidenced low correlation between two...

10.1099/jmm.0.47732-0 article EN Journal of Medical Microbiology 2008-04-24

The neonatal Fc receptor (FcRn) is important for the metabolic fate of IgG antibodies in vivo. Analysis interaction between FcRn and vitro might provide insight into structural functional integrity therapeutic that may affect pharmacokinetics (PK) We developed a standardized pH gradient affinity liquid chromatography method with conditions closely resembling physiological mechanism FcRn. This allows separation molecular isoforms, degradation products engineered molecules based on their to...

10.4161/mabs.24981 article EN mAbs 2013-05-29

Preserving the chemical and structural integrity of therapeutic antibodies during manufacturing storage is a major challenge pharmaceutical development. Oxidation Fc methionines Met252 Met428 frequently observed, which leads to reduced affinity FcRn faster plasma clearance if present at high levels. Because oxidation occurs in both positions simultaneously, their individual contribution concomitant changes pharmacokinetic properties has not been clearly established. A novel pH-gradient...

10.4161/mabs.29601 article EN mAbs 2014-06-17

The 2019 13th Workshop on Recent Issues in Bioanalysis (WRIB) took place New Orleans, LA, USA April 1–5, with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, week-long event – full immersion week bioanalysis, biomarkers, immunogenicity gene therapy. As usual, it specifically designed to facilitate sharing, reviewing, discussing agreeing...

10.4155/bio-2019-0271 article EN Bioanalysis 2019-12-01

Monoclonal IgG antibodies are the fastest growing class of biologics, but large differences exist in their plasma half-life humans. Thus, to design with favorable pharmacokinetics, it is crucial identify determinants such differences. Here, we demonstrate that variable region sequences greatly affect cellular uptake and subsequent recycling rescue from intracellular degradation by endothelial cells. When masked cognate antigen, influences both transport behavior binding neonatal Fc receptor...

10.1016/j.isci.2022.103746 article EN cc-by-nc-nd iScience 2022-01-10

Abstract Deregulation of the proto‐oncogene MYC by specific chromosomal translocations has been shown to be essential but not sufficient for development Burkitt's lymphoma (BL). To identify other genes which either mark important steps in tumorigenesis or reflect cellular differentiation state BL cells we have compared tumor immortalized lymphoblastoid B subtractive hybridization. We identified a complementary DNA clone encodes novel member superfamily GTP‐binding (G) protein‐coupled...

10.1002/eji.1830221107 article EN European Journal of Immunology 1992-11-01

The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and intervals, application route tissue penetration. In indications where health-care providers patients can choose between several efficacious safe options, convenience (determined by dosing interval or application), which is mainly driven PK properties, drug selection. Therapeutic have greatly different even if they identical Fc domains show no target-mediated disposition. Biophysical like surface...

10.1080/19420862.2019.1683432 article EN cc-by-nc mAbs 2019-11-26

Abstract Purpose: CD40 agonists hold great promise for cancer immunotherapy (CIT) as they enhance dendritic cell (DC) activation and concomitant tumor-specific T-cell priming. However, the broad expression of accounts sink side effects, hampering efficacy anti-CD40 antibodies. We hypothesized that these limitations can be overcome by selectively targeting agonism to tumor. Therefore, we developed a bispecific FAP-CD40 antibody, which induces stimulation solely in presence fibroblast protein...

10.1158/1078-0432.ccr-20-4001 article EN Clinical Cancer Research 2021-03-26

Emicizumab is a humanised, bispecific monoclonal antibody mimicking the cofactor function of activated factor (F)VIII. It indicated for routine prophylaxis bleeding episodes in persons with haemophilia A (PwHA) with/without FVIII inhibitors.

10.1111/hae.14398 article EN cc-by-nc Haemophilia 2021-09-04

To produce healthy offspring, an organism must pass on its genetic material with high fidelity. In many species, this is accomplished by primordial germ cells (PGCs), which give rise to sperm or eggs. PGCs are often specified far from the future gonads and migrate through developing tissues reach them. Failure do so can result in infertility cell tumours. While PGC migration well characterized some very little known about their mammalian embryos. Here, we performed dynamic quantitative...

10.1101/2025.03.03.641275 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2025-03-03

The success of recombinant monoclonal immunoglobulins (IgG) is rooted in their ability to target distinct antigens with high affinity combined an extraordinarily long serum half-life, typically around 3 weeks. pharmacokinetics IgGs intimately linked the recycling mechanism neonatal Fc receptor (FcRn). For half-life therapeutic IgGs, highly pH-dependent interaction FcRn needs be balanced allow efficient binding and release at slightly acidic pH physiological pH, respectively. Some like...

10.1074/mcp.m116.064675 article EN cc-by Molecular & Cellular Proteomics 2017-01-07

Background: In some people with Parkinson's disease (PD), α-synuclein (αSyn) accumulation may begin in the enteric nervous system (ENS) decades before development of brain pathology and diagnosis. Objective: To determine how different types severity intestinal inflammation could trigger αSyn ENS subsequent pathology. Methods: We assessed effects modulating short- long-term experimental colitis on gut transgenic wild type mice by immunostaining gene expression analysis. effect brain, we...

10.17879/freeneuropathology-2021-3326 article EN DOAJ (DOAJ: Directory of Open Access Journals) 2021-01-01

BACKGROUND: As of 2004, the European Pharmacopoeia demands that plasma pools for production anti‐D immunoglobulin should not contain more than 10 4 IU per mL parvovirus B19 (B19V) DNA. Hence, before pooling, highly viremic donations have to be identified, and after pooling level B19V DNA must determined. The performance a new real‐time PCR test (Roche, Mannheim, Germany) was studied, using extractor (NucliSens, bioMerieux, Boxtel, Netherlands) isolation nucleic acid, quantification...

10.1046/j.0041-1132.2004.00610.x article EN Transfusion 2004-01-01

With only a few exceptions, the ribonucleoprotein telomerase has been found in malignant, but not benign tissues. Telomerase is thus potentially new diagnostic marker. Carcinoma of urinary bladder most frequent malignant tumor tract and, after prostatic carcinoma, second common malignancy genitourinary system. In order to evaluate capabilities carcinomas, four cell lines derived from human urothelial carcinomas bladder, 75 tissue samples eight normal urothelium, 40 washings and 30 urine were...

10.3892/ijo.9.6.1169 article EN International Journal of Oncology 1996-12-01

The aim of our study was to prospectively evaluate the potential diagnostic value and clinical applicability quantitative analysis telomerase subunits gene expression in urine for noninvasive detection bladder cancer. Expression levels human reverse transcriptase (hTERT) RNA (hTR) were analyzed by real-time polymerase chain reaction (RT-PCR) samples from 163 subjects with cancer 237 controls (163 individuals benign genitourinary diseases; 74 healthy subjects). sensitivity, specificity...

10.1002/ijc.21168 article EN International Journal of Cancer 2005-05-17
Coming Soon ...